[Skip to Content]
[Skip to Content Landing]
March 1988

Successful Intravenous Immune Globulin Therapy for Human Immunodeficiency Virus—Associated Thrombocytopenia

Author Affiliations

From the Section of Hematology/Oncology, Department of Medicine, Northwestern University Medical School, Chicago.

Arch Intern Med. 1988;148(3):695-697. doi:10.1001/archinte.1988.00380030201031

• High-dose intravenous (IV) Immune globulin was used to treat human immunodeficiency virus (HIV)—associated thrombocytopenia four times in three patients. The average platelet count at initiation of therapy was 12×109/L (12×103/mm3), and the platelet count after therapy was 159×109/L (159×103/mm3), giving a mean Increase of 147×109/L 147×103/mm3) (1225%). The conditions of two of these patients were refractory to corticosteroids, but giving IV immune globulin along with steroids appeared to enhance the response to IV immune globulin. A review of the literature revealed that 53 (88%) of 60 patients with HIV-associated thrombocytopenia responded to IV immune globulin with platelet counts greater than 50× 109/L (50×103/mm3). We conclude that IV immune globulin therapy achieves transient elevations in platelet counts to levels that control bleeding and permit surgery in patients with severe, HIV-associated thrombocytopenia.

(Arch Intern Med 1988;148:695-697)